Bio

David Glazer advises and represents a wide range of private and public companies in the life sciences industry, focusing on licensing and collaboration agreements, corporate partnering arrangements, strategic alliances, asset acquisitions and divestitures, joint ventures, strategic manufacturing, supply and distribution agreements, and co-development and co-commercialization arrangements. Working closely with clients to understand their businesses, David structures and negotiates deals to meet their objectives and find practical solutions to complex problems. David’s clients range from biotechnology startups to global Fortune 100 pharmaceutical companies throughout the United States, Europe, and Asia. David focuses on the specialized needs of pharmaceutical, biotechnology, medical device, digital health, and specialty pharmaceutical companies. David brings a background in drug and medical device development and commercialization, early-stage research and development of late-stage product deals, and issues related to the life sciences industry such as indication, field, and territory splitting, and he works on early-stage research collaborations, global alliances, and developing and commercializing products. David’s guidance supports clients at every stage of the development cycle, from clinical to commercial, including complex deals involving gene and cell therapies. He authors and co-authors articles about the life sciences industry, as well as guest lectures to law students and MBA candidates about licensing in the life sciences industry. For his work in the life sciences field, David has been recognized by numerous publications and ranking organizations, including LMG Life Sciences and Chambers.